GWS
MCRB icon

Glassman Wealth Services’s Seres Therapeutics MCRB Stock Holding History

Glassman Wealth Services’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-12
Closed -$6K – 1541
2020
Q4 		$6K Buy
+12
New +$7.03K ﹤0.01% 832
2016
Q4 		– Sell
-5
Closed -$1K – 685
2016
Q3 		$1K Buy
+5
New +$1.75K ﹤0.01% 432

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Glassman Wealth Services's MCRB Position: Q1 2021 in Review

Glassman Wealth Services sold out of Seres Therapeutics (MCRB) in Q1 2021, closing a stake of 12 shares — an estimated $6K sold.

Glassman Wealth Services first reported a position in MCRB in Q3 2016 and held it in 2 quarters. The position peaked at $6K in Q4 2020. 152 funds tracked by Wall St. Rank hold MCRB as of Q1 2021.

  • Glassman Wealth Services reported no remaining Seres Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Glassman Wealth Services sold 12 Seres Therapeutics shares in Q1 2021, an estimated $6K.
  • Glassman Wealth Services first reported a position in Seres Therapeutics in Q3 2016 and held it in 2 quarters.
  • Glassman Wealth Services's Seres Therapeutics position peaked at $6K in Q4 2020.
  • 152 funds tracked by Wall St. Rank held Seres Therapeutics as of Q1 2021.

Based on Glassman Wealth Services's 13F filing for Q1 2021, filed 5 May 2021.